The digital press release with multimedia content can be accessed here: Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta ® ...
Copenhagen, Denmark; August 20, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of Kesimpta ® (ofatumumab) injection for ...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
The digital press release with multimedia content can be accessed here: Basel, January 29, 2021 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (ofatumumab) ...
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of ...
People with relapsing-remitting and active secondary-progressive multiple sclerosis (MS), as well as those with clinically isolated syndrome (CIS, an initial neurological episode), have a new ...
Novartis’ first TV ad for Kesimpta offers the prospect of less drama—less relapsing multiple sclerosis drama, that is. During the commercial, phrases representing that drama such as “unpredictable ...
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. EAST HANOVER, N.J., Aug. 20, 2020 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results